Daily Bio News Summary — 2026-09-17: Two platform bets on bispecifics, a steady FDA clearance flow, and another CEO change

Thursday’s harvest added 19 items to the news collection, drawn from six sources: Endpoints News (6), PR Newswire FDA (6), Fierce Pharma (3), Fierce Biotech (2), BioSpace (1), and STAT News (1). Two sources came back empty this run — Reuters Biopharma served a bot wall rather than its homepage, and BioPharma Dive continues to render dates in a format the parser cannot verify, so both were skipped conservatively rather than guessed at.

The category mix is split almost evenly between regulatory and clinical news (8 items) and business and strategy (8), with two executive appointments and a single therapeutics-development item filling out the batch.

Read as a set, the day has a clear center of gravity: large pharmas are paying for antibody-engineering platforms rather than assets, while the FDA quietly keeps clearing products across drugs, generics and diagnostics.

Platform deals, not asset deals

Two of the day’s largest commitments were to discovery engines rather than late-stage programs.

Endpoints News reports that Roche is turning to Dualitas to find new bispecific approaches for immunology (Endpoints News, 2026-09-17), and Fierce Biotech frames the same arrangement as a $1B deal to collaborate on bispecific screening (Fierce Biotech, 2026-09-17). This is a screening-and-discovery collaboration — Roche is buying optionality on a bispecific pipeline, not a clinical asset.

The second is larger and has a metabolic angle. Endpoints News reports that Lilly-backed Orbis has struck a macrocycle deal with Novo worth up to $1.4B (Endpoints News, 2026-09-17), while Fierce Biotech describes it as Novo exploring macrocycle potential in a $1.4B Danish biotech pact (Fierce Biotech, 2026-09-17). Both frames agree on the shape: an upfront-plus-milestones structure against an early-stage platform, in this case oral macrocyclic peptides.

That both deals involve immunology or metabolism — and both are structured as platform access — is the pattern worth noting. Neither company is buying a Phase 3 readout.

A steady FDA clearance flow

The regulatory items are notable less for any single one than for their breadth across product types.

On the drug side, PR Newswire FDA carries Nuvation Bio’s approval of a supplemental new drug application for IBTROZI (taletrectinib), with an updated duration of response in previously untreated ROS1-positive non-small cell lung cancer (PR Newswire FDA, 2026-09-17). The same feed has DifGen Pharmaceuticals receiving US approval for epinephrine injection USP single-dose vials (PR Newswire FDA, 2026-09-16) — a generic rather than a novel product, which is itself a reminder that the approval list tracks the whole market.

Diagnostics and devices fill out the picture: Aptitude announced a 510(k) clearance for a next-generation Metrix COVID test (PR Newswire FDA, 2026-09-16) and ZBeats received clearance for the ZBPro Diagnostic v2.0, supporting ECG analysis up to 14 days (PR Newswire FDA, 2026-09-15). Earlier-stage, IASO Bio’s CD20-targeted in vivo CAR-T therapy IASO208 received FDA IND clearance (PR Newswire FDA, 2026-09-16).

Outside the US, Fierce Pharma reports that AZ and Daiichi’s Enhertu secured a long-sought NICE blessing for NHS use (Fierce Pharma, 2026-09-16) — a reimbursement milestone rather than a regulatory one, and often the harder of the two to obtain.

Two setbacks with different shapes

Longeveron had the day’s sharpest market reaction: BioSpace reports its shares crashed as a stem cell therapy flunked a mid-stage cardiovascular trial (BioSpace, 2026-09-16). This is a straightforward clinical failure, and it follows a well-worn pattern for cell therapies in cardiovascular indications.

Lisata tells a more textured story. Fierce Biotech reports that after a failed acquisition, Lisata found a lifeline in a merger with Marea (Fierce Biotech, 2026-09-17). The project’s second act is a merger rather than a wind-down — a resolution that has become more common as biotechs with failed deals seek alternatives to liquidation.

Executive changes

Two appointments today, both reflecting talent movement rather than distress. Bavarian Nordic named Tarja Stenvall as its new CEO (Endpoints News, 2026-09-17), and Fierce Pharma reported that former PHM CEO Andrea Palmer is taking the top job at Assembled Intelligence (Fierce Pharma, 2026-09-17). The latter is a move from a healthcare-media/commercial role into a health-tech company — the kind of crossover that has been picking up as data and AI vendors staff up commercially.

Litigation and public health

BMS and Ono are suing Amgen over a proposed Opdivo biosimilar (Fierce Pharma, 2026-09-16). Biosimilar litigation is the standard mechanism by which originators defend franchise exclusivity, and it tends to be a leading indicator of how soon a competing product reaches market.

On the public-health side, the WHO expressed cautious optimism about efforts to control an Ebola outbreak in the DRC (STAT News, 2026-09-16). This is the only item in the batch that is not commercial in character, and the word “cautious” is doing real work in that headline.

What this batch is NOT telling us

A few of the usual suspects are absent, and their absence is informative:

• No AI-bio financing. After yesterday’s Novo–Anthropic-style activity, today brought no AI drug discovery rounds or partnerships. The platform deals that did land are wet-lab platforms, not computational ones.
• No IPOs. The only capital-markets item is a footnote — Endpoints reporting that Hong Kong is investigating the Cloudbreak IPO alongside Gilead’s HIV PrEP agreements (Endpoints News, 2026-09-17).
• No China licensing out. Yesterday’s batch had China-origin dealmaking; today’s largest non-US item is a Korean preclinical pact — SK’s $315M deal for a preclinical Parkinson’s prospect (Fierce Biotech, 2026-09-17).
• No Phase 3 readouts. The clinical news today is a Phase 2 failure and a label expansion. No pivotal data.

Reading order

If you have fifteen minutes rather than an afternoon:

1. Roche–Dualitas and Novo–Orbis (Endpoints News, 2026-09-17) — read as a pair, they are the clearest statement of how platform value is being priced right now.
2. Longeveron’s trial failure and share crash (BioSpace, 2026-09-16) — the day’s cleanest negative signal for cell therapy in cardiovascular disease.
3. BMS/Ono v. Amgen (Fierce Pharma, 2026-09-16) — the biosimilar fight that will determine Opdivo’s competitive timeline.
4. Enhertu’s NICE recommendation (Fierce Pharma, 2026-09-16) — a reminder that reimbursement, not approval, is the binding constraint in Europe.

How to read the underlying articles

Each item above is backed by a markdown file in src/content/news/. Every file carries a sourceUrl pointing at the original article, a sourceName, and a pubDate. Where a story was covered by more than one outlet, only the highest-priority source was written to the collection — so the file you find is the canonical version, not necessarily the first one published.

Frontmatter is the only source of record for this summary. No figures, quotes or readouts beyond those in the harvested headlines and decks have been added.

All items in this batch

1. Longeveron’s shares crash as stem cell therapy flunks mid-stage cardio trial — BioSpace, 2026-09-16
2. Lilly-backed Orbis does up to $1.4B macrocycle deal with Novo — Endpoints News, 2026-09-17
3. Bavarian Nordic names Tarja Stenvall as new CEO — Endpoints News, 2026-09-17
4. Roche turns to Dualitas to find new bispecific approaches for immunology — Endpoints News, 2026-09-17
5. Roche eyes label expansion for Lunsumio after confirmatory lymphoma trial win — Endpoints News, 2026-09-17
6. General Catalyst’s ambitions to change how hospitals operate are taking clearer shape — Endpoints News, 2026-09-17
7. Gilead reaches HIV PrEP agreements; Hong Kong investigates Cloudbreak IPO — Endpoints News, 2026-09-17
8. After failed acquisition, Lisata finds lifeline in Marea merger — Fierce Biotech, 2026-09-17
9. SK pens $315M pact for preclinical Parkinson’s prospect — Fierce Biotech, 2026-09-17
10. Ex-PHM CEO Andrea Palmer takes top job at Assembled Intelligence — Fierce Pharma, 2026-09-17
11. AZ, Daiichi’s Enhertu nabs long-sought NHS blessing from NICE — Fierce Pharma, 2026-09-16
12. BMS, Ono sue Amgen over proposed Opdivo biosimilar — Fierce Pharma, 2026-09-16
13. Nuvation Bio announces FDA approval of supplemental new drug application for IBTROZI (taletrectinib) — PR Newswire FDA, 2026-09-17
14. Aptitude announces FDA 510(k) clearance of next-generation Metrix COVID test — PR Newswire FDA, 2026-09-16
15. DifGen Pharmaceuticals announces US FDA approval of epinephrine injection USP, 1 mg/mL, single-dose vials — PR Newswire FDA, 2026-09-16
16. IASO Bio’s CD20-targeted in vivo CAR-T therapy IASO208 receives FDA IND clearance — PR Newswire FDA, 2026-09-16
17. ZBeats receives FDA clearance for ZBPro Diagnostic v2.0, supporting ECG analysis up to 14 days — PR Newswire FDA, 2026-09-15
18. Waters sets benchmark for standardized spectral flow cytometry with commercial launch of BD FACSDiscover A7 cell analyzer — PR Newswire FDA, 2026-09-14
19. WHO expresses cautious optimism about bid to control Ebola outbreak in DRC — STAT News, 2026-09-16